TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14755505
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC)
Study: 11090571
Drug: CC (2
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CC (2 g/kg body wt of CHO in a 25.7% CHO beverage 30 min before and 2 g/kg of CHO in a 6.4% CHO solution throughout SS)
Study: 11090571
Drug: PC (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC (placebo 30 min before and 2 g/kg body wt of CHO in a 6.4% CHO solution throughout SS)
Study: 11090571
Drug: CP (2
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CP (2 g/kg body wt of CHO in a 25.7% CHO beverage 30 min before and placebo throughout SS)
Study: 9069692
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (40-hour training program)
Study: 8417381
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with fluorouracil
Study: 8417381
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy without fluorouracil
Study: 8417381
Drug: Smoking during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking during radiation therapy
Study: 3770045
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (2 mg/m2) every 3 weeks for a maximum of eight courses followed by DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D (1.5 mg/m2 on Day 1)
Study: 3770045
Drug: DTIC (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC (250 mg/m2 i.v. daily X 5) and Actinomycin D (1.5 mg/m2 on Day 1)
Study: 3770045
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum followed by chemotherapy
Study: 31314785
Drug: Concurrent-100% feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent-100% feedback
Study: 31314785
Drug: Concurrent-50% feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent-50% feedback
Study: 20632322
Drug: Metronidazole 10
Normalized name: metronidazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 10 per cent ointment, 0.7 g applied perianally three times daily
Study: 20632322
Drug: Metronidazole 10
Normalized name: metronidazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 10 per cent ointment
Study: 15978101
Drug: S18886 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S18886 1 mg
Study: 15978101
Drug: S18886 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S18886 2.5 mg
Study: 15978101
Drug: S18886 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S18886 5 mg
Study: 15978101
Drug: S18886 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: S18886 10 mg
Study: 15978101
Drug: S18886 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: S18886 30 mg
Study: 12814908
Drug: Thiamine-enriched beer
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine-enriched beer (10 mg of thiamine)
Study: 12814908
Drug: Normal beer
Normalized name: BEER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal beer (0 mg of thiamine)
Study: 10997482
Drug: SCE (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCE (synthetic conjugated estrogens, A) 0.3 mg, 0.625 mg, or 1.25 mg per day
Study: 1448777
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose epinephrine infusion
Study: 30629183
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (250 mg intramuscular injections every 2 weeks for 22 weeks)
Study: 21427372
Drug: Hydrocortisone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (200 mg/d for 5 days, followed by 100 mg on day 6 and 50 mg on day 7)
Study: 11158489
Drug: Point-of-care evidence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care evidence delivery regarding the use and duration of antibiotics for otitis media.
Study: 2403603
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulfamethoxazole and trimethoprim (1600/320 mg) plus loperamide hydrochloride (4 mg loading dose, then 2 mg after each loose stool)
Study: 2403603
Drug: Sulfamethoxazole and
Normalized name: sulfamethoxazole and trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole and trimethoprim (800/160 mg orally twice daily)
Study: 2403603
Drug: Loperamide hydrochloride
Normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loperamide hydrochloride (4 mg loading dose, then 2 mg after each loose stool)
Study: 30677766
Drug: MP-AzeFlu (137/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP-AzeFlu (137/50 μg AZE/FP per spray)
Study: 30677766
Drug: AZE (137
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZE (137 μg/spray)
Study: 25462393
Drug: Short-term psychotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychotherapy (Solution-Focused Therapy, SFT, n=97)
Study: 25462393
Drug: Short-term therapies
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term therapies (SFT and SPP)
Study: 23963054
Drug: Oral α‐methylparatyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral α‐methylparatyrosine (AMPT)
Study: 7890905
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg orally daily)
Study: 3224534
Drug: Thiopental (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (loading dose of 15 mg/kg over 30 min followed by constant infusion)
Study: 27027616
Drug: N-acetylcysteine (N-AC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (N-AC) 70 mg kg(‐1)
Study: 24632280
Drug: FIRM-blinded therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIRM-blinded therapy
Study: 23400715
Drug: Sifalimumab (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sifalimumab (0.3, 1.0, 3.0, or 10.0 mg/kg)
Study: 22131734
Drug: Pradhamana Nasya
Normalized name: Hyaluronic acid (NASHA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradhamana Nasya followed by oral Trayodashanga Kwatha with Madhu (Group C)
Study: 12851520
Drug: Antihypertensive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive agents (beta-blocker, non-beta-blocker, or beta-blocker plus non-beta-blocker)
Study: 9231864
Drug: Opioid drug
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid drug via patient-controlled analgesia (PCA) systems for 7 days or more
Study: 7956549
Drug: PG05 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG05 0.25 mg
Study: 7956549
Drug: ONO-802 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-802 0.125 mg
Study: 3310925
Drug: Nonathymulin 5
Normalized name: NONATHYMULIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonathymulin 5 mg/day
Study: 23362148
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic fields (PEMFs) treatment
Study: 17348883
Drug: Standard cylindrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cylindrical implants
Study: 30902603
Drug: Tapered implants
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tapered implants
Study: 22672713
Drug: Both implant
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implant designs
Study: 5109411
Drug: Intrathecal chemotherapy
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal chemotherapy with methotrexate
Study: 5109411
Drug: Intrathecal chemotherapy
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal chemotherapy with cytosine arabinoside
Study: 5109411
Drug: Prophylactic intrathecal
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intrathecal chemotherapy (control group)
Study: 28164731
Drug: PEC I
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEC I (consume 50 mL of PEC/day)
Study: 28164731
Drug: PEC II
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEC II (consume 100 mL of PEC/day)
Study: 28164731
Drug: Placebo (consume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (consume 50 mL of simulated prune drink)
Study: 25740672
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol 5 mg/mL solution applied twice daily for an average of 4.0 ± 1.1 months
Study: 25740672
Drug: Combined sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sequential pulsed dye and Nd:YAG laser treatment for an average of 5.5 ± 0.9 months
Study: 17076630
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of timolol and dorzolamide
Study: 11696618
Drug: Standard-fractionated radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-fractionated radiotherapy (60 Gy/30 fractions/6 weeks) with concurrent cisplatin (80 mg/m² on day 1) and vindesine (3 mg/m² on days 1 and 8 every 4 weeks)
Study: 11696618
Drug: Accelerated-hyperfractionated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated-hyperfractionated radiotherapy (54 Gy/36 fractions/3.6 weeks) with concurrent cisplatin (80 mg/m² on day 1) and vindesine (3 mg/m² on days 1 and 8 every 4 weeks)
Study: 9043729
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg glycopyrrolate im
Study: 9043729
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg hyoscine hydrobromide po
Study: 9043729
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg hyoscine hydrobromide im
Study: 2407084
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg orally 3 times daily (group 1, n = 115)
Study: 2407084
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg orally 3 times daily plus dipyridamole 75 mg orally 3 times daily (group 2, n = 117)
Study: 2407084
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg orally 3 times daily (group 1)
Study: 2407084
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg orally 3 times daily plus dipyridamole 75 mg orally 3 times daily (group 2)
Study: 7002183
Drug: Aspirin (250,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (250, 500, and 1000 mg)
Study: 7002183
Drug: New formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulations of Optalidon (aminopyrine replaced by propyphenazone)
Study: 7002183
Drug: New formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulations of Tonopan (aminopyrine replaced by propyphenazone)
Study: 7002183
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aminopyrine, caffeine, and butalbarbital (Optalidon)
Study: 7002183
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aminopyrine, caffeine, butalbarbital, and dihydroergotamine (Tonopan)
Study: 16126743
Drug: Usual daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual daily activities
Study: 31724026
Drug: Fixed-Duration Chemotherapy-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-Duration Chemotherapy-Free Treatment
Study: 28545978
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg injections every 4 weeks for 12 weeks
Study: 20102872
Drug: Glycemia levels
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycemia levels categorized as < or = 100 mg/dL (5.5 mmol/L)
Study: 1611640
Drug: Diltiazem hydrochloride
Normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem hydrochloride 120 mg
Study: 1611640
Drug: Diltiazem hydrochloride
Normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem hydrochloride 240 mg
Study: 1611640
Drug: Diltiazem hydrochloride
Normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem hydrochloride 360 mg
Study: 1611640
Drug: Diltiazem hydrochloride
Normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem hydrochloride 480 mg
Study: 30584293
Drug: IND/MF (QMF149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/MF (QMF149) 150/160 µg once daily
Study: 30584293
Drug: Sal/Flu (50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sal/Flu (50/500 µg twice daily)
Study: 11276406
Drug: Antidepressant treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatments (specifics not provided)
Study: 11276406
Drug: Nonexperimental evidence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonexperimental evidence of antidepressant use (specifics not provided)
Study: 11276406
Drug: Comprehensive model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive model for assessing antidepressant use in youths
Study: 8385750
Drug: Natural conjugates
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natural conjugates oestrogen (0.625 mg per diem per os) plus MAP (10 mg per diem per os) for 12 days a month
Study: 29117990
Drug: Midostaurin (PKC412)
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Midostaurin (PKC412) administered daily for 4 days
Study: 25274978
Drug: 9-valent HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent HPV vaccine (HPV6/11/16/18/31/33/45/52/58)
Study: 24423823
Drug: Chemotherapy (cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin, gemcitabine, paclitaxel, and pemetrexed) under the guidance of molecular markers
Study: 24423823
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m(2) days 1 and 8 with 21 days as a cycle
Study: 18849230
Drug: Internal thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal thoracic artery preparation with intact pleura (Group 1)
Study: 16449899
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment (BT)
Study: 11042989
Drug: 15 percent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 percent CP whitening agent
Study: 11042989
Drug: 10 percent
Normalized name: BENZOYL PEROXIDE 10 g in 100 mL TOPICAL LOTION [SMART RELEASE BPO 10 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 percent CP whitening agent
Study: 8778601
Drug: Regularly scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regularly scheduled inhaled albuterol
Study: 8778601
Drug: As-needed inhaled
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As-needed inhaled albuterol
Study: 2875904
Drug: Brompheniramine maleate
Normalized name: Brompheniramine Maleate
DrugBank: Brompheniramine (DB00835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brompheniramine maleate (12 mg twice daily in sustained release form)
Study: 24115082
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab 162 mg every 2 weeks (q2w)
Study: 24115082
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab 162 mg weekly (qw)
Study: 24115082
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab 81 mg every 2 weeks (q2w)
Study: 22152401
Drug: Pharmacotherapy +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy + clinical management (MED)
Study: 22152401
Drug: Pill-placebo +
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill-placebo + clinical management (PBO)
Study: 15301658
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch plus bupropion SR (150 mg per day)
Study: 21507585
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch plus placebo
Study: 9349066
Drug: morphine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (75 micrograms.kg‐1)
Study: 3896355
Drug: Combination instruments
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination instruments (masker plus hearing aid)
Study: 23891925
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg, twice daily)
Study: 20374562
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/day) for 3 months
Study: 20374562
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/day) for 9 months
Study: 7981560
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/day)
Study: 12168782
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 10 mg/day for 10 days
Study: 12625969
Drug: Metronidazole treatment
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole treatment (rectally for at least 4 days)
Study: 7496647
Drug: Paroxetine (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20, 40, or 60 mg)
Study: 1784590
Drug: Pyridostigmine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (30 mg.3/day)
Study: 6807568
Drug: Verapamil, 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 480 mg/day
Study: 28296763
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg M-001
Study: 28296763
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg M-001
Study: 20935327
Drug: Cognitive-linguistic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-linguistic treatment (CLT), 6 months, at least 2 hours per week
Study: 20935327
Drug: Communicative treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Communicative treatment, 6 months, at least 2 hours per week
Study: 20935327
Drug: Cognitive-linguistic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-linguistic treatment (CLT)
Study: 19522781
Drug: Home-based ecologically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based ecologically based family therapy (EBFT)
Study: 19522781
Drug: Office-based functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based functional family therapy (FFT)
Study: 15055821
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months treatment with growth hormone (2 IU/day)
Study: 11218239
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (mean, 0.12 mg/kg/day) plus oral glutamine (mean, 28 g/day) and parenteral glutamine (mean, 5.2 g/day) for 28 days
Study: 11218239
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone and glutamine treatment
Study: 9355019
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (AT) for 18 +/- 6 months
Study: 9355019
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (AT)
Study: 3315478
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (MPSS) 30 mg/kg
Study: 31462735
Drug: Obinutuzumab (G)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance
Study: 23030309
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug (candesartan cilexetil 16 mg)
Study: 23030309
Drug: Reference drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug (candesartan cilexetil 16 mg)
Study: 18044014
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of isoproterenol (20 mug/min) during repeat ablation
Study: 15019120
Drug: Glutamine granules
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine granules 0.5 g/kg orally for 14 days
Study: 15019120
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dosage as glutamine) for 14 days
Study: 9935254
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trovafloxacin once daily for 10 days
Study: 7755476
Drug: cilazapril 2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril 2.5-5 mg per day
Study: 7755476
Drug: atenolol 25-100
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 25-100 mg per day